B38.1
B38.1
规格:
货期:
编号:TS212629
品牌:Testobio
| 产品名称： | B38.1 |
|---|---|
| 商品货号： | TS212629 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Carcinoma,sarcoma |
| Applications： | The antibody reacts weakly with extracts of both metastases and with live cells, and strongly with live BT-20 (ATCC HTB-19), MCF7 (ATCC HTB-22) and or ZR-75-1 (ATCC CRL-1500) mammary carcinoma cells. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human mammary tumor cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human mammary tumor cells |
| Comments： | Animals were immunized with membrane enriched fractions of extracts from either of two human breast tumor metastases to the liver (Met 1 and Met 2). Spleen cells were fused with NS-1 myeloma cells. The antibody reacts weakly with extracts of both metastases and with live cells, and strongly with live BT-20 (ATCC HTB-19), MCF7 (ATCC HTB-22) and or ZR-75-1 (ATCC CRL-1500) mammary carcinoma cells. The antibody does not react with liver extracts or a variety of live normal and sarcoma cells. |
| Complete Growth Medium： | Culture Medium: Iscoves modified Dulbeccos medium, 80%; fetal bovine serum, 20%. |
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:5 is recommended Medium Renewal: 3 times per week Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 92.5%; DMSO, 7.5% |
| Isotype： | IgG1 |
| Name of Depositor： | NIH |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Colcher D, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA 78: 3199-3203, 1981. PubMed: 6789331 Colcher D, et al. Process for producing monoclonal antibodies reactive with human breast cancer. US Patent 4,522,918 dated Jun 11 1985 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
B38.1
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | B38.1 |
|---|---|
| 商品货号： | TS212629 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Carcinoma,sarcoma |
| Applications： | The antibody reacts weakly with extracts of both metastases and with live cells, and strongly with live BT-20 (ATCC HTB-19), MCF7 (ATCC HTB-22) and or ZR-75-1 (ATCC CRL-1500) mammary carcinoma cells. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human mammary tumor cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human mammary tumor cells |
| Comments： | Animals were immunized with membrane enriched fractions of extracts from either of two human breast tumor metastases to the liver (Met 1 and Met 2). Spleen cells were fused with NS-1 myeloma cells. The antibody reacts weakly with extracts of both metastases and with live cells, and strongly with live BT-20 (ATCC HTB-19), MCF7 (ATCC HTB-22) and or ZR-75-1 (ATCC CRL-1500) mammary carcinoma cells. The antibody does not react with liver extracts or a variety of live normal and sarcoma cells. |
| Complete Growth Medium： | Culture Medium: Iscoves modified Dulbeccos medium, 80%; fetal bovine serum, 20%. |
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:5 is recommended Medium Renewal: 3 times per week Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 92.5%; DMSO, 7.5% |
| Isotype： | IgG1 |
| Name of Depositor： | NIH |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Colcher D, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA 78: 3199-3203, 1981. PubMed: 6789331 Colcher D, et al. Process for producing monoclonal antibodies reactive with human breast cancer. US Patent 4,522,918 dated Jun 11 1985 |
